Pays: Arménie
Langue: anglais
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
captopril
KRKA d.d.
C09AA01
captopril
25mg
tablets
(20/2x10/) in blister
Prescription
Registered
2018-10-03
I(RI(I-\
KAPTOPRIL tablets 25 mg
VOL:
1; P: 79/269
1.3.1
SPC,
Labeling and Package Leaflet
JIUCToK-RKJla,UbIUl
(O,UUOBPCMCHJlOHHCTpYKl.\lU1no
MC,UIIUHHCKOMY"pIIMCHeHUIO
JleKapCTBeHlIoro
CpcllcTBa)
KAnTOnPlfJI
Ta6J1eTKIl
12,5
Mr,
25
Mr,
50
Mr
KaIlTonpl1JJ
TOllTOBoe
Ha3BaHHC
KAf1TOTIPI1J1
06lUaIJ
xapaKTepllcTuKa
_Me:JICoYllopooHoe_
_HenameHmOBaHHoe_
_HG3BalWe_
KanTOlIpHJI
(Captopril)
_Onucallue_
_Ta6nemKlt_
_12,5_
_.HZ:_
Kpyrnhle,
cnerKa
,[IBOllKoBhmYKJlhle
Ta6JIeTl(J1 6eJIoro
UBeTa co CKoweHHhlMI1
KPaJIJlUI.
_Ta6nemKlI_
25
_M2:_
KpyrJll:,le
Ta6J1CTKH 6eJloro
UBeTa
co
CKoweHHhlMH
KpaJIMH H HaCeqKOH Ha
O,UHOI{cTopoHe.
_Ta6.~e111KZI_
_50_
_J1!tz:_
Kpyrnhle,
cnerKa
.D:BollKoBhmYKJlhle
Ta6neTKI1
6enoro
llBeTa
co
CKOllleHHhlMH
KpaJIJIIH I{
HaCeq}(OM Ha O,UHOHcTopoHe.
COCT3S
O,llHa m6JTeTJapMaKoTepanCSTll'IeCKaH
rpynna
II KO,UKJlaCClIljJlIKal.\l1II JleKapCTBCHJlOrO cpe,UCTB3
HHrlt6HTOP
ru;lHoTeH3HH-npeBpall.laIOll.lero
q)epMeHTa (ATIapMaKOJlOTlI'leCKlle
CBoiicTB3
_([)apMaKOOllllaJItllK(l_
KamonpHfl
HHm6HpyeT
aHrHOTeH3HH-npeBpall.lalOll.lHH
Hblii
3
Lire le document complet
PI_Text042404_2 – Updated: Page 1 of 16 1. NAME OF THE MEDICINAL PRODUCT Kaptopril 25 mg tablets Kaptopril 50 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25 mg or 50 mg captopril. Excipient: 25 mg tablets 50 mg tablets lactose 47.50 mg/tablet 95.00 mg/tablet For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. The tablets of 25 mg are white, round, slightly biconvex tablets with bevelled edges and scored on one side. The score line is not intended for breaking the tablet. The tablets of 50 mg are white, round, slightly biconvex tablets with bevelled edges and a score on one side. The score line is not intended is not intended for breaking the tablet. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS - Hypertension: The management of mild to moderate hypertension. In severe hypertension it should be used where standard therapy is ineffective or inappropriate. - Congestive heart failure: Captopril is indicated for the treatment of congestive heart failure. The drug should be used together with diuretics, and when appropriate, digitalis and beta-blockers. In patients on doses of over 100 mg daily plus or minus a diuretic, in those with severe renal impairment or those with severe congestive heart failure use of captopril should be under specialist supervision. - Myocardial infarction: Short-term (4 weeks) treatment: Captopril is indicated in any clinically stable patient within the first 24 hours of an infarction. Long-term prevention of symptomatic heart failure: Captopril is indicated in clinically stable patients with asymptomatic and symptomatic left ventricular dysfunction (ejection fraction < 40%) following myocardial infarction to improve survival, delay the onset of symptomatic heart failure, reduce hospitalisations for heart failure and reduce recurrent myocardial infarction and coronary revascularisation procedures. Before starting therapy, cardiac function should be determined by radionuclide ventriculography or echocardiography. - Type I Diabe Lire le document complet